| 22 | 0 | 121 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:探讨螺内脂联合地尔硫卓治疗舒张性心力衰竭的临床效果。方法:将2013年6月至2014年6月化州市人民医院收治的120例舒张性心力衰竭患者分为对照组(螺内酯联合倍他乐克)和研究组(螺内酯联合地尔硫卓),每组各60例。对比两组治疗前后E峰、A峰、E/A比值、6 min步行距离、脑钠肽水平灯指标的差异。结果:治疗前两组E峰、A峰、E/A比值、6 min步行距离、脑钠肽水平比较,差异无统计学意义(P>0.05);治疗后,两组上述指标优于治疗前,且研究组优于对照组(P<0.05)。结论:螺内脂联合地尔硫卓治疗舒张性心力衰竭,可有效改善患者的舒张性心功能不全,效果良好,值得推广应用。
Abstract:Objective: To investigate the clinical effect of Spironolactone and Diltiazem for treatment of diastolic heart failure( DHF). Methods: A total of 120 patients with DHF hospitalized in Huazhou Municipal People's Hospital between June 2013 and June 2014 were included in the study,and divided into the control group( Spironolactone and Betaloc) and the study group( Spironolactone and Diltiazem)( n = 60 each). The differences in the E peak,A peak,E / A ratio,6 min walking distance,and brain natriuretic peptide( BNP)level between the two groups before and after the treatment were compared. Results: There were no statistically significant differences in the E peak,A peak,E / A ratio,6 min walking distance,and BNP level between the two groups before the treatment( P > 0. 05). These parameters of the two groups after the treatment were significantly better than those before the treatment,and the study group was superior to the control group( P <0. 05). Conclusion: Spironolactone and Diltiazem can be used to treat DHF,which can effectively improve diastolic cardiac insufficiency,and justifies widespread use.
[1]林黎明,杨小杰.螺内酯联合地尔硫卓治疗舒张性心力衰竭的临床疗效分析[J].中南药学,2014,5(1):74-76.
[2]武国新.螺内酯联合地尔硫卓治疗舒张性心力衰竭疗效观察[J].中国现代药物应用,2014,12(7):155-156.
[3]刘华,陈子平.舒张性心力衰竭患者应用螺内酯联合地尔硫卓治疗的效果分析[J].临床医学工程,2014,16(6):755-756.
[4]朱红光,王清燕.地尔硫卓联合螺内酯治疗舒张性心力衰竭的疗效观察[J].实用心脑肺血管病杂志,2013,8(4):114.
[5]胡波.依那普利·倍他乐克与螺内酯联合治疗慢性心力衰竭的临床观察[J].临床医学,2013,33(8):20-21.
[6]高福英.倍他乐克联合依那普利治疗舒张性心力衰竭的疗效观察[J].当代医学,2012,18(10):7-9.
基本信息:
中图分类号:R541.6
引用信息:
[1]谢爵隆.螺内酯联合地尔硫卓治疗舒张性心力衰竭的临床观察[J].广州医科大学学报,2015,43(04):76-78.
2015-08-15
2015-08-15